Beam And Verve Benefit From Buzz Around Base-Editing Therapies

Excitement Around Next-Gen Gene-Editing

 
• By Andrew McConaghie
  
Sekar Kathiresan
Verve's CEO Sekar Kathiresan. The company is working in partnership with Beam Therapeutics on bringing base edited gene therapies to market. • Source: Verve Therapeutics
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip